Clinical Trial Update: Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas [Phase 2]

View source ↗

Summary

A Phase II/pilot study evaluating second-generation anti-CEA designer T cells in adenocarcinomas has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Cancer

Drugs mentioned

• Second generation anti-CEA designer T cells (CAR-T cells targeting carcinoembryonic antigen (CEA))

Snippet

Sponsor: Roger Williams Medical Center | Conditions: Metastatic Cancers | Phase 2 | Status: SUSPENDED